Subtype
Lung Neuroendocrine Carcinoma
CI-CAN-00003107Explore in graph →
389 active trials6 approved drugs6 evidence items
- NCIt
- C45569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003107Explore in graph →
Clinical trials
1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (159)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT04659785 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | unknown | Phase 1 / Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Dec 9, 2020 |
| clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03547804 | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer(MK 01) | completed | Phase 2 | 31 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT04647357 | A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 30, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04620837 | Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy(PINNACLE) | terminated | Phase 1 / Phase 2 | 172 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04535739 | PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study | unknown | Phase 3 | 414 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT04501029 | A Study of Gimatecan (ST1481) in Small Cell Lung Cancer | unknown | Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT03607682 | Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer | terminated | N/A | 2 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | AbbVieINDUSTRY | 5 | Jul 17, 2020 | clinicaltrials |
| NCT03389087 | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03904719 | CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) | unknown | Phase 2 | 30 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04451460 | Effect of Hyponatremia in Small Cell Lung Cancer | completed | — | 466 | Ankara City Hospital BilkentOTHER | 0 | Jun 30, 2020 | clinicaltrials |
| NCT01803269 | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer | terminated | Phase 2 | 29 | University of ChicagoOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT04440800 | Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment(WATTOX) | unknown | — | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT04291937 | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Jun 19, 2020 | clinicaltrials |
| NCT03983759 | Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04404543 | A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer | unknown | Phase 1 | 71 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | May 27, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT00080015 | Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 9 | IpsenINDUSTRY | 0 | Apr 29, 2020 | clinicaltrials |
| NCT04363255 | First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC | unknown | Phase 2 | 20 | Taizhou HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy(CARACTER) | terminated | N/A | 55 | Amphia HospitalOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT00921739 | Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies(ESIMRT) | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT04314297 | Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | unknown | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 19, 2020 | clinicaltrials |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | terminated | Phase 1 | 23 | University of Maryland, BaltimoreOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01876446 | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02735980 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 2 | 133 | Eli Lilly and CompanyINDUSTRY | 10 | Mar 17, 2020 | clinicaltrials |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 | 28 | AbbVieINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT03585998 | Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer | unknown | Phase 2 | 51 | Samsung Medical CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00613626 | Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 74 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02551432 | Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer(MISP-MK3475) | completed | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT03613597 | Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer | unknown | Phase 2 | 118 | Guizhou Medical UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03613753 | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 72 | ShengFa SuOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03741829 | TS Overexpression in SCLC: Mechanism and Therapeutic Targeting | completed | — | 12 | Wake Forest University Health SciencesOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | unknown | Phase 2 / Phase 3 | 313 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02058056 | Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC | completed | N/A | 44 | Swiss Cancer InstituteOTHER | 1 | Jan 29, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2020source: clinicaltrials